Releases Geral
AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 11 de dezembro de 2023
AiViva Biopharma
- Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma
COSA MESA, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) — AiViva Biopharma Inc., a clinical-stage biotechnology company, announced completion of their first trial administering AIV001 (axitinib) to patients diagnosed with basal cell carcinoma (BCC) tumors. AIV001 is AiVivas novel intradermally administered product designed for local, prolonged treatment effect for dermatological conditions.
The phase 1/2 multicenter, open-label clinical trial evaluated AIV001 in patients with superficial, nodular or mixed BCC tumors. The study enrolled a total of 26 subjects who were studied in four ascending dose cohorts. Subjects receive up to three treatments during the course of the study and monitored for safety, skin tolerability, and efficacy measured by clinical and histological clearance of malignant basal cells in the lesions. We are excited to have completed this safety study that is demonstrating excellent skin tolerability and a dose response. This promising data allows AiViva multiple options to develop it further, including but not limited to seeking a strategic partner for this compound, said Diane Tang-Liu, PhD, President and CEO of AiViva.
The most common cancer worldwide is nonmelanoma skin cancer with the BCC subtype being the most prevalent that occurs in the skin. Millions of new cases are diagnosed every year in the U.S. alone due to the increase in sun exposure and aging population. Current treatment often requires surgery that can lead to scarring. It is exciting and important to have AiViva Biopharma develop a drug, with a new mechanism of action, that has the potential to treat BCC that avoids surgery, said Brian Berman, MD, PhD, Professor Emeritus of Derma-tology and Dermatologic Surgery at The University of Miami Miller School of Medicine.
About AiViva Biopharma, Inc.
AiViva is a clinical stage biotech company led by a team of seasoned industry experts with proven track record in drug development and commercialization. AiViva has developed innovative approaches to address high unmet medical needs by transforming treatment paradigms through focal therapies that target diseases of neovascularization, abnormal cell proliferation, and fibrosis. Core competencies include development of novel drugs using proprietary technologies, including JEL, in specialty therapeutic areas of dermatology, ophthalmology, urology and oncology. Please visit www.aiviva.com to learn more.
Contact:
AiViva Biopharma
office@aiviva.com
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Geral PNUD pede urgência nas ações pelo clima em campanha global
25 de março de 2024Nova York --(DINO - 25 mar, 2024) - Telespectadores ao redor do mundo que assistirem aos boletins meteorológicos terão uma surpresa – uma previsão do te
Saiba Mais -
Releases Geral Pandemia tem impacto duradouro no mercado wellness
7 de junho de 2024São Paulo--(DINO - 07 jun, 2024) - A pandemia de Covid-19 provocou transformações culturais profundas em diversos setores, e o mercado wellness não foi exce&c
Saiba Mais -
Releases Geral Brindes personalizados se destacam em eventos corporativos
17 de julho de 2024(DINO - 17 jul, 2024) - Que atire a primeira bolsa retornável aquele que nunca saiu contente de um evento, como seminários ou feiras, por ter recebido diversos brind
Saiba Mais